Jpmorgan Chase & CO Magenta Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.36 - $1.59 $894 - $3,952	-2,486 Reduced 77.96%	703 $0
Q3 2022 Nov 14, 2022	SELL	$1.26 - $2.09 $579,164 - $960,676	-459,654 Reduced 99.31%	3,189 $4,000
Q2 2022 Aug 11, 2022	BUY	$0.97 - $3.08 $18,363 - $58,307	18,931 Added 4.26%	462,843 $555,000
Q1 2022 May 11, 2022	BUY	$2.55 - $5.23 $181,684 - $372,632	71,249 Added 19.12%	443,912 $1.29 Million
Q4 2021 Feb 10, 2022	SELL	$4.43 - $8.33 $630,672 - $1.19 Million	-142,364 Reduced 27.64%	372,663 $1.65 Million
Q3 2021 Nov 12, 2021	BUY	$6.07 - $9.89 $3.13 Million - $5.09 Million	515,027 New	515,027 $3.75 Million

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.